Circulating tumor DNA-based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.

被引：0
|
作者：
Fusco, Brendon
Tsai, Jill
Clemens, Keelia
Gulhati, Pat
机构：
[1] Rutgers Canc Inst New Jersey, Dept Hematol & Med Oncol, New Brunswick, NJ USA
[2] Guardant Hlth Inc, Redwood City, CA USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
747
引用
收藏
页码：747 / 747
页数：1
相关论文
共 50 条
  • [1] Comparative analysis of the targetable landscape in KRAS-mutant and wild-type pancreatic adenocarcinoma.
    Knepper, Todd C.
    Kim, Dae Won
    Mauer, Elizabeth
    Ronski, Karyn
    Gulhati, Pat
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma.
    Gulhati, Pat
    Pandya, Karan
    Dada, Hiba I.
    Cogle, Christopher R.
    Starr, Jason S.
    Kalmadi, Sujith R.
    Braiteh, Fadi S.
    Drusbosky, Leylah
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
    Ashok Kumar, Prashanth
    Serinelli, Serenella
    Zaccarini, Daniel J.
    Huang, Richard
    Danziger, Natalie
    Janovitz, Tyler
    Basnet, Alina
    Sivapiragasam, Abirami
    Graziano, Stephen
    Ross, Jeffrey S.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Genomic Landscape of Clinically Advanced KRAS Wild-Type Pancreatic Ductal Adenocarcinoma (PDA)
    Serinelli, Serenella
    Zaccarini, Daniel
    Parimi, Vamsi
    Huang, Richard
    Danziger, Natalie
    Janovitz, Tyler
    Ross, Jeffrey
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1229 - 1231
  • [5] Genomic Landscape of Clinically Advanced KRAS Wild-Type Pancreatic Ductal Adenocarcinoma (PDA)
    Serinelli, Serenella
    Zaccarini, Daniel
    Parimi, Vamsi
    Huang, Richard
    Danziger, Natalie
    Janovitz, Tyler
    Ross, Jeffrey
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1229 - 1231
  • [6] Circulating tumor DNA-based genomic landscape of early-onset pancreatic cancer
    Barnett, Reagan
    Dada, Hiba I.
    Drusbosky, Leylah
    Clemens, Keelia
    Hochster, Howard S.
    Gulhati, Pat
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] Genomic loss of the wild-type KRAS allele in pancreatic tumor progression and metastasis
    Yan, Han
    Yu, Chih-Chieh
    Fine, Stuart
    Lee, Ayman
    Yang, Ye-Ran
    Yan, Juan
    Garcia-Carracedo, Dario
    Karg, Dillon
    Cheung, Edwin
    Friedman, Richard
    Chen, Emily
    Luo, Ji
    Miao, Yi
    Qiu, Wanglong
    Su, Gloria
    CANCER RESEARCH, 2019, 79 (24)
  • [8] Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma.
    Yousef, Mahmoud M. G.
    Hurd, Mark W.
    Yousef, Abdelrahman M. G.
    Snyder, Rebecca A.
    Knafl, Mark
    Fanaeian, Mohammad Mahdi
    Chacko, Ray
    Peterson, Jennifer
    Smaglo, Brandon George
    Wolff, Robert A.
    Pant, Shubham
    Lee, Michael Sangmin
    Overman, Michael J.
    Tzeng, Ching-Wei D.
    Katz, Matthew H. G.
    Wang, Huamin
    Maitra, Anirban
    Ludmir, Ethan B.
    Shen, John Paul Y. C.
    Zhao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 636 - 636
  • [9] Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).
    George, Ben
    Greenbowe, Joel R.
    Hendifar, Andrew Eugene
    Golan, Talia
    Javle, Milind M.
    Maitra, Anirban
    Bahary, Nathan
    Schrock, Alexa Betzig
    Stephens, Philip J.
    Miller, Vincent A.
    Ross, Jeffrey S.
    Yakirevich, Evgeny
    Ritch, Paul S.
    Thomas, James P.
    Ali, Siraj Mahamed
    Singhi, Aatur D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma
    Salem, Mohamed E.
    Al-hajeili, Marwan R.
    Dyson, Gregory
    Stanski, Natalja
    Jain, Tania
    Mahaseth, Hemchandra
    Choi, Minsig
    Shields, Anthony Frank
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345